AU2003295738A1 - Novel lapachone compounds and methods of use thereof - Google Patents

Novel lapachone compounds and methods of use thereof Download PDF

Info

Publication number
AU2003295738A1
AU2003295738A1 AU2003295738A AU2003295738A AU2003295738A1 AU 2003295738 A1 AU2003295738 A1 AU 2003295738A1 AU 2003295738 A AU2003295738 A AU 2003295738A AU 2003295738 A AU2003295738 A AU 2003295738A AU 2003295738 A1 AU2003295738 A1 AU 2003295738A1
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
compound
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003295738A
Other languages
English (en)
Inventor
Samuel K. Ackerman
Zhiwel Jiang
Chiang Li
Youzhi Li
Dasharatha Reddy
June Salvesen
Xiangao Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of AU2003295738A1 publication Critical patent/AU2003295738A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92Naphthofurans; Hydrogenated naphthofurans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74Naphthothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2003295738A 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof Abandoned AU2003295738A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42728302P 2002-11-18 2002-11-18
US60/427,283 2002-11-18
US10/622,854 2003-07-17
AUPCT/US03/22631 2003-07-17
PCT/US2003/037219 WO2004045557A2 (en) 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2003295738A1 true AU2003295738A1 (en) 2004-06-15

Family

ID=34375156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003295738A Abandoned AU2003295738A1 (en) 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof

Country Status (12)

Country Link
US (1) US20040266857A1 (https=)
EP (1) EP1567515A4 (https=)
JP (1) JP2006508147A (https=)
CN (1) CN1729183A (https=)
AR (1) AR056613A1 (https=)
AU (1) AU2003295738A1 (https=)
BR (1) BR0316296A (https=)
CA (1) CA2506340A1 (https=)
EA (1) EA200500849A1 (https=)
MX (1) MXPA05005314A (https=)
TW (1) TW200510367A (https=)
WO (1) WO2004045557A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575580A4 (en) 2002-12-02 2009-06-10 Arqule Inc METHOD FOR TREATING CARCINOMA
WO2005053682A2 (en) 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
WO2005082357A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating hematologic tumors
EP1722775A1 (en) 2004-02-20 2006-11-22 Arqule, Inc. Use of beta-lapachone for treating hematologic tumors
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
CA2555941A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treatment of colon cancer
EP1722777A2 (en) * 2004-02-20 2006-11-22 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
EP1722776A2 (en) * 2004-02-20 2006-11-22 Arqule, Inc. Use of beta-lapachone as a broad spectrum anti-cancer agent
WO2005082353A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating or preventing cancer
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
US7812051B2 (en) 2004-08-11 2010-10-12 Arqule, Inc. Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential
EP1836320A2 (en) 2005-01-07 2007-09-26 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2006128120A2 (en) * 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof
WO2007139569A1 (en) * 2006-05-26 2007-12-06 Arqule, Inc. Novel lapachone compounds and methods of use thereof
TW200824692A (en) 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
US8389568B2 (en) 2007-03-16 2013-03-05 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
EP2152686B1 (en) 2007-04-30 2014-12-17 ArQule, Inc. Hydroxy sulfonate of quinone compounds and their uses
WO2009051752A1 (en) * 2007-10-16 2009-04-23 Arqule, Inc. Novel lapachone compounds and methods of use thereof
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
CN102985053A (zh) * 2010-06-01 2013-03-20 百利-亚尔香芬公司 口腔异味控制方法和产品
WO2017106624A1 (en) 2015-12-18 2017-06-22 The Board Of Regents Of The University Of Texas System Napthoquinones, pro-drugs, and methods of use thereof
KR101735275B1 (ko) 2016-12-20 2017-05-16 아주대학교산학협력단 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2011455B (en) * 1977-12-21 1982-03-03 Ici Ltd Chemical process
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
JP2005538981A (ja) * 2002-07-17 2005-12-22 アーキュル, インコーポレイテッド 活性化チェックポイント療法およびこれらの使用方法

Also Published As

Publication number Publication date
AR056613A1 (es) 2007-10-17
WO2004045557A3 (en) 2004-08-12
US20040266857A1 (en) 2004-12-30
TW200510367A (en) 2005-03-16
EA200500849A1 (ru) 2006-02-24
CA2506340A1 (en) 2004-06-03
MXPA05005314A (es) 2005-10-19
EP1567515A4 (en) 2008-04-23
WO2004045557A2 (en) 2004-06-03
JP2006508147A (ja) 2006-03-09
BR0316296A (pt) 2005-12-13
CN1729183A (zh) 2006-02-01
EP1567515A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
AU2003295738A1 (en) Novel lapachone compounds and methods of use thereof
EP1877097B1 (en) Aminoacid conjugates of beta-lapachone for tumor targeting
CN102002051B (zh) 具有抗肿瘤活性的ent-6,7-开环贝壳杉烯型冬凌草甲素衍生物、其制备方法及用途
DE69913697T2 (de) Naphtho- und dihydrobenzothiophenderivate als cytotoxische antitumormittel
WO2004026253A2 (en) Novel lapacho compounds and methods of use thereof
AU2005316739A1 (en) Spiro derivatives as lipoxygenase inhibitors
CA2685739C (en) Hydroxy sulfonate of quinone compounds and their uses
WO1996022089A1 (en) p-HETEROATOM-SUBSTITUTED PHENOLS AND USES THEREOF
JPS61158978A (ja) 抗緑内障剤としての置換芳香族スルホンアミド類
JP2011528691A (ja) 血管拡張活性を有する硝酸イソソルビド
WO2009051752A1 (en) Novel lapachone compounds and methods of use thereof
KR20050089007A (ko) 신규한 라파콘 화합물 및 이의 사용 방법
US7902354B2 (en) Lapachone compounds and methods of use thereof
EP1212315A1 (en) Novel chalcones
WO2018153328A1 (zh) 双黄酮-铁配合物及其制备方法和应用
WO2006128120A2 (en) Novel lapachone compounds and methods of use thereof
WO2015104298A2 (de) Polyphenol-konjugate
ES2283649T3 (es) Compuesto retinoides heterociclicos.
CN101115734A (zh) 作为脂氧化酶抑制剂的螺环衍生物
HK1139411B (en) Hydroxy sulfonate of quinone compounds and their uses
EP0450588A1 (de) Substituierte 3-Thia- bzw. 3-Oxa-alkyl-Flavone, Verfahren zu ihrer Herstellung, Verwendung derselben, Arzneimittel auf Basis dieser Verbindungen sowie Zwischenprodukte
AU2002363170A1 (en) Heterocyclic retinoid compounds

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period